Secukinumab provides sustained improvement in signs and symptoms and low radiographic progression in patients with psoriatic arthritis: 2-year (end-of-study) results from the FUTURE 5 study

Lignende værker

• Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double-blind, phase III FUTURE 5 study
  af: Mease, Philip, et al.
  Udgivet: (2018)
• Secukinumab provides sustained low rates of radiographic progression in psoriatic arthritis: 52-week results from a phase 3 study, FUTURE 5
  af: van der Heijde, Désirée, et al.
  Udgivet: (2020)
• Brief Report: Secukinumab Provides Significant and Sustained Inhibition of Joint Structural Damage in a Phase III Study of Active Psoriatic Arthritis
  af: van der Heijde, Désirée, et al.
  Udgivet: (2016)
• Secukinumab in the treatment of psoriatic arthritis: efficacy and safety results through 3 years from the year 1 extension of the randomised phase III FUTURE 1 trial
  af: Mease, Philip J, et al.
  Udgivet: (2018)
• Secukinumab sustains improvement in signs and symptoms of psoriatic arthritis: 2 year results from the phase 3 FUTURE 2 study
  af: McInnes, Iain B, et al.
  Udgivet: (2017)